Virtual Library
Start Your Search
C. Lai
Author of
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-057 - Diagnostic Value of Tumor Markers in Lung Adenocarcinoma-Associated Cytologically Positive and Negative Pleural Effusions (ID 4009)
14:30 - 14:30 | Author(s): C. Lai
- Abstract
Background:
Cytology fails to detect neoplastic cells in 40–50% of malignant pleural effusions (PEs), which commonly accompany lung adenocarcinomas.
Methods:
PE samples were collected from 74 lung adenocarcinoma patients with associated cytologically positive (41) and negative (33) effusions, and from 99 patients with benign conditions including tuberculosis, pneumonia, congestive heart failure, and liver cirrhosis. We evaluated the diagnostic sensitivity and optimal cutoff points for tumor markers Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen (CEA) to distinguish lung adenocarcinoma-associated cytologically negative pleural effusions (LAC-CNPEs) from benign PEs.
Results:
Mean levels of Her-2/neu, Cyfra 21-1, and CEA were significantly higher in LAC-CNPEs than in benign pleural effusions (P = 0.0050, = 0.0039, and < 0.0001, respectively). The cutoff points for Her-2/neu, Cyfra 21-1, and CEA were optimally set at 3.6 ng/mL, 60 ng/mL, and 6.0 ng/mL. Their sensitivities ranged from 12.1%, to 30.3%, to 63.6%, respectively. CEA combined with Cyfra 21-1 increased diagnostic sensitivity to 66.7%.
Conclusion:
Combining CEA with Cyfra 21-1 will provide the best differentiation between LAC-CNPEs and benign PEs with two tumor markers to date, and allows early diagnosis and early treatment for two-thirds of affected patients.
